How do you know which treatment is right for a patient? It can be a tricky question to answer. Below are some patient profiles to help you identify patients that may benefit from GSK’s COPD treatments.
Recently diagnosed with COPD, struggles with breathlessness despite daily SABA use.
She is on treatment with an ICS/LABA, symptomatic and at risk of an exacerbation:
- Has worsening of symptoms, or
- Has experienced an exacerbation treated with antibiotics or oral corticosteroids, in the past 12 months.
Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA. 3
The safety and efficacy profile of our COPD treatments have been studied in clinical trials. Do you want to learn more? You can explore the studies here:
Benefit from expert opinion and free downloadable resources, including training devices and COPD Assessment Test (CAT) pads.
CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic receptor antagonist